Sign in

CIK 0001434316

  • Non-accelerated filer
  • Smaller reporting company

FATE THERAPEUTICS INC

Sign in to watch
Ticker
FATE
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
651311552
Phone
+1 858-875-1803
Business address
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA, 92131
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$13,525
in 1 filing

Net −$13,525. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Adawi Kamal −$14K Chief Financial Officer sold 7% of stake

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2021-12-13 Valamehr Bahram Chief R&D Officer Sale −1,600 $49.27 $79K 156,698
2021-12-13 Valamehr Bahram Chief R&D Officer Option exercise · Stock Option (Right to Buy) +25,000 61,156
2021-12-10 Chu Yu-Waye Senior VP Clinical Development Option exercise +7,500 $16.32 $122K 133,258
2021-12-10 Chu Yu-Waye Senior VP Clinical Development Sale −2,097 $49.32 $103K 131,161
2021-12-10 Chu Yu-Waye Senior VP Clinical Development Sale −900 $50.42 $45K 130,261
2021-12-10 Chu Yu-Waye Senior VP Clinical Development Sale −1,045 $51.08 $53K 129,216
2021-12-10 Chu Yu-Waye Senior VP Clinical Development Sale −1,822 $52.37 $95K 127,394
2021-12-10 Chu Yu-Waye Senior VP Clinical Development Sale −1,031 $53.66 $55K 126,363
2021-12-10 Chu Yu-Waye Senior VP Clinical Development Sale −600 $54.58 $33K 126,763
2021-12-10 Chu Yu-Waye Senior VP Clinical Development Sale −5 $55.54 $278 125,758
2021-12-10 Chu Yu-Waye Senior VP Clinical Development Option exercise · Stock Option (Right to Buy) −7,500 105,000
2021-11-19 Wolchko J Scott President and CEO Grant or award +86,475 480,268
2021-11-19 Valamehr Bahram Chief R&D Officer Grant or award +60,958 156,698
2021-11-19 TAHL CINDY General Counsel and Secretary Grant or award +60,958 169,006
2021-11-19 Plavsic Mark Chief Technical Officer Grant or award +59,540 97,540
2021-11-19 Dulac Edward J III Chief Financial Officer Grant or award +59,540 111,944
2021-11-19 Chu Yu-Waye Senior VP Clinical Development Grant or award +60,958 125,758
2021-11-18 Wolchko J Scott President and CEO Option exercise +20,000 $2.70 $54K 413,793
2021-11-18 Wolchko J Scott President and CEO Sale −20,000 $54.27 $1.1M 393,793
2021-11-18 Wolchko J Scott President and CEO Option exercise · Stock Option (right to buy) −20,000 79,446

Page 15 of 26 · 503 trades